Asd

Asd articles

New experimental drug reduces autism like behaviors
National Institutes of Health researchers have reversed behaviors in mice resembling two of the three core symptoms of autism spectrum disorders (ASD). An experimental compound, called GRN-529, increased social interactions and lessened repetitive self-grooming behavior in a strain of mice that normally display such autism-like behaviors, the researchers say.

Genetic changes in 3 genes linked to autism spectrum disorders
Mutations in three new genes have been linked to autism, according to new studies including one with investigators at Mount Sinai School of Medicine. All three studies include lead investigators of the Autism Sequencing Consortium (ASC).

Environment factors important than genetic in autism
Shared environmental factors – experiences and exposures common to both twin individuals – accounted for 55% of strict autism and 58% of more broadly defined autism spectrum disorders (ASD), revealed by researchers. Genetic heritability accounted for 37% of autism and 38% of ASD.

1 year well baby check up approach - catching signs of autism early
A novel strategy developed by autism researchers at the University of California, San Diego School of Medicine, called "The One-Year Well-Baby Check Up Approach," shows promise as a simple way for physicians to detect cases of Autism Syndrome Disorder (ASD), language or developmental delays in babies at an early age.

Half of all children with autism wander and bolt from safe places
The Interactive Autism Network (IAN), reveals the preliminary results of the first major survey on wandering and elopement among individuals with autism spectrum disorders (ASD), and announces the launch of a new research survey on the association between pregnancy factors and ASD.

Palomar laser device for skin in Germany
Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a maker of aesthetic laser devices (laser device for skin), announced that it will establish a subsidiary in Germany to help the company gain international market share.

QNEXA for Weight Loss in obesity - CONQUER study
VIVUS, Inc. (NASDAQ: VVUS) announced that detailed results from the 56-week CONQUER study were published in The Lancet evaluating the efficacy and safety of investigational drug QNEXA in 2,487 patients across 93 sites in the US.

Clinical trial of human embryonic stem cell therapy in US
Geron Corporation (Nasdaq: GERN) announced the enrollment of the first patient in the company's clinical trial of human embryonic stem cell (hESC)-derived oligodendrocyte progenitor cells, GRNOPC1.

Genomic sequencing of difficult breast cancers
Life Technologies Corporation (NASDAQ: LIFE) announced that it is collaborating with the Translational Genomics Research Institute (TGen) and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies.

Brain imaging may help diagnose autism disorder
Children with autism spectrum disorders (ASDs) process sound and language a fraction of a second slower than children without ASDs, and measuring magnetic signals that mark this delay may become a standardized way to diagnose autism.

4 new risk factors for prostate cancer - deCODE genetics
deCODE genetics (Nasdaq:DCGN) announced that a team of its scientists and academic colleagues from Finland, Spain, the Netherlands and the United States have published the discovery of four novel single-letter variations in the sequence of the human genome (SNPs) conferring increased risk of prostate cancer.

Orexigen's Contrave trials successful for obesity treatment
Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that all three remaining Phase 3 trials evaluating Contrave(R) (bupropion SR/naltrexone SR), its investigational drug for the treatment of obesity, met their co-primary endpoints.

Lupus drug Benlysta effective for SLE patients
Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) announced that BENLYSTA (belimumab, formerly LymphoStat-B®) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE).

FASD children have more behavioral problems than ADHD children
Children with fetal alcohol spectrum disorders (FASD) have a high risk of psychiatric problems, particularly attention deficit hyperactivity disorder (ADHD), conduct disorder, or both.

Influenza patients may get Shionogi's Peramivir soon
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced positive results from two Phase 3 studies of intravenous (i.v.) peramivir in patients with seasonal influenza.

Option Inferior Vena Cava Filter gets FDA clearance in US
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Option(TM) Inferior Vena Cava (IVC) Filter in the United States, for use in both permanent and retrievable indications.

Complete response letter for Cinryze for hereditary angioedema
ViroPharma Incorporated (Nasdaq: VPHM) announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) related to its supplemental Biologics License Application (sBLA) for Cinryze(TM) (C1 esterase inhibitor [human]) as a treatment for acute attacks of hereditary angioedema (HAE).

Positive clinical trial results of vilazodone for depression
Clinical Data, Inc. (NASDAQ: CLDA) announced positive top-line results from the second of two Phase III trials of its investigational compound, vilazodone, for the treatment of major depressive disorder (MDD).

Citalopram ineffective for children with autism
Citalopram, a medication commonly prescribed to children with autism spectrum disorders (ASD), was no more effective than a placebo at reducing repetitive behaviors, according to researchers.

Champion clinical trial program of cangrelor discontinued
The Medicines Company (NASDAQ: MDCO) announced that it is discontinuing its Phase 3 CHAMPION clinical trial program of cangrelor in patients undergoing percutaneous coronary intervention (PCI).

Fanapt iloperidone approved for schizophrenia treatment
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the US Food and Drug Administration (FDA) has granted marketing approval of Fanapt (iloperidone) for the acute treatment of adult patients with schizophrenia.

New drug to improve walking ability in multiple sclerosis people
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that the U.S. Food and Drug Administration (FDA) has accepted the Fampridine-SR New Drug Application (NDA) for filing, assigning Priority Review and a Prescription Drug User Fee Act (PDUFA) date of October_22, 2009.

Stop Using Hydroxycut Dietary Supplements for weight loss
The U.S. Food and Drug Administration is warning consumers to immediately stop using Hydroxycut products by Iovate Health Sciences Inc., of Oakville, Ontario and distributed by Iovate Health Sciences USA Inc. of Blasdell, N.Y. Some Hydroxycut products are associated with a number of serious liver injuries. Iovate has agreed to recall Hydroxycut products from the market.

Autism linked to being firstborn, breech births or older moms
Children who are firstborn or breech or whose mothers are 35 or older when giving birth are at significantly greater risk for developing an autism spectrum disorder, University of Utah School of Medicine researchers have reported in a new study with Utah children.

Prostate cancer vaccine Provenge prolongs survival
Dendreon Corporation (Nasdaq: DNDN) announced that the pivotal Phase 3 IMPACT study of PROVENGE (sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of improving overall survival compared to a placebo control.

GE and Intel to form healthcare alliance
GE (NYSE:GE) and Intel Corporation (NASDAQ: INTC) announced today an alliance to market and develop home-based health technologies that will help seniors live independently and patients with chronic conditions manage their care from the comfort of their home or wherever they choose.

Autism distorts developing brain in children
Individuals with autism spectrum disorders (ASD) tend to stare at people's mouths rather than their eyes.

Positive results of Albuferon in Chronic Hepatitis C
Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in ACHIEVE 1, a Phase 3 clinical trial of Albuferon in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C (p=0.0008).

ViroPharma's Maribavir failed in bone marrow transplant patients
ViroPharma Incorporated (Nasdaq: VPHM) announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint.

Autism spectrum disorder linked to preterm birth
Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC), in collaboration with other medical centers, have found that children born more than three months premature, are at three times the risk for screening positive on the modified checklist for autism in toddlers (M-CHAT).

Human clinical trial of embryonic stem cell therapy approved
Geron Corporation (Nasdaq: GERN) announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury.

Abraxis BioScience to Create Abraxis Health - Pioneering Personalized Medicine
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced that the Board of Directors has approved a strategic plan to create Abraxis Health, Inc., an independent, stand-alone company to be spun-off from Abraxis BioScience that will be dedicated to becoming a fully integrated, next-generation, evidence-based, personalized healthcare company.

New drug tasimelteon for jet lag
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) reports publication in The Lancet, one of the world's leading medical journals, results of clinical trials of its novel circadian regulator, experimental compound tasimelteon (VEC-162).

Kinship of couples may determine number of children
In a paper published by deCODE genetics (Nasdaq:DCGN) scientists establish a substantial and consistent positive correlation between the kinship of couples and the number of children and grandchildren they have.

27% lower mortality in top hospitals, finds HealthGrades
Patients treated at top-rated hospitals in US are nearly one-third less likely to die, on average, than those admitted to all other hospitals, according to a study released by HealthGrades (Nasdaq: HGRD), the leading independent healthcare ratings organization.

Chromosomal abnormalities play substantial role in autism
Genome-wide scans of families affected by autism spectrum disorder (ASD) have revealed new evidence that previously unknown chromosomal abnormalities have a substantial role in the prevalent developmental disorder, according to a report published online Jan. 17th in the American Journal of Human Genetics, a publication of Cell Press.

GVAX cancer immunotherapy improves prostate cancer survival
Cell Genesys, Inc. (Nasdaq: CEGE) announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, has completed a pre-planned interim analysis and has recommended that the study continue, as GVAX cancer immunotherapy improves prostate cancer patients survival.

37 Asd articles listed above.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
4.18